Unity biotechnology, inc. (UBX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating expenses:
Research and development

19,265

18,207

17,777

18,468

16,505

16,331

14,353

15,198

13,025

11,591

9,599

9,213

6,970

General and administrative

5,953

4,907

5,692

4,970

4,477

4,328

4,389

3,842

3,457

2,578

2,484

2,485

2,070

Change in fair value of contingent consideration

-221

-24

-1,115

1,032

-1,245

-

635

1,758

-

-

-

-

-

Impairment of long-lived assets

2,159

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

27,156

23,090

22,354

24,470

19,737

22,808

19,377

20,798

16,482

14,169

12,083

11,698

9,040

Loss from operations

-27,156

-23,090

-22,354

-24,470

-19,737

-22,808

-19,377

-20,798

-16,482

-12,787

-12,083

-11,698

-9,040

Interest income

527

627

756

900

1,006

1,066

1,068

826

352

321

348

278

108

Other expense, net

-1,409

-

-

-

-36

-

-

-

-

-

-

-

-

Other expense, net

-

-

112

103

-

-

37

30

3

-

15

8

2

Net loss

-28,038

-18,027

-21,710

-23,673

-18,767

-21,917

-18,346

-20,002

-16,133

-12,544

-11,750

-11,428

-8,934

Other comprehensive loss
Unrealized gain on marketable debt securities, net of tax

283

-5

-18

94

114

24

-42

61

-34

-

-

-

-

Unrealized gain (loss) on marketable securities, net of tax

-

-

-

-

-

-

-

-

-

-

16

-18

-

Comprehensive loss

-27,755

-18,032

-21,728

-23,579

-18,653

-21,893

-18,388

-19,941

-16,167

-12,646

-11,734

-11,446

-8,934

Net loss per share, basic and diluted

-0.59

-0.37

-0.51

-0.56

-0.44

3.20

-0.45

-0.76

-4.69

-3.82

-3.63

-3.62

-2.90

Weighted average number of shares used in computing net loss per share, basic and diluted

47,544

46,899

42,965

42,442

42,190

42,285

41,057

26,298

3,437

3,319

3,236

3,154

3,079